Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Manuel Touris"'
Autor:
Manuel Touris, Goretti Duran, Elena Gallardo, Rafael López, María Jesús Lamas, Emilia Balboa, Yolanda Vidal, Francisco Barros, Beatriz Bernardez, Angel Carracedo
Publikováno v:
Pharmacogenomics. 12:433-442
Aim: Polymorphisms in the metabolism, detoxification or DNA repair pathways have been proposed as potential predictors of response to 5-fluorouracil and oxaliplatin. We have studied the predictive value of a set of germline genetic polymorphisms in m
Autor:
María Jesús Lamas, Rafael López, Borja Franco, Bibiana Sanchez, Goretti Duran, Mar Lale, Manuel Touris, Nieves Mayo, Juan Cueva, Alicia Mosquera, Beatriz Bernardez, Sara Blanco, Alba Hernández García, Elena López
Publikováno v:
Journal of Clinical Oncology. 36:e18872-e18872
e18872Background: Most data on infusion related reactions (IRR) come from clinical trials. Its severity and management are issues addressed in many studies, however, the impact in real life in term...
Autor:
Rafael López, Elena López, Goretti Duran, Maria Francisca Vazquez, A. García, Cristina Gonzalez-Anleo, Manuel Touris, Bibiana Sanchez, María Jesús Lamas, Alicia Mosquera, Beatriz Bernardez, Marca Diaz, Alberto Llorente, Yolanda Vidal
Publikováno v:
Journal of Clinical Oncology. 35:e18249-e18249
e18249 Background: Trifluridine/tipiracil (TAS) is a new alternative in metastatic colorectal cancer patients (pts) previously treated with fluoropyrimidines, oxaliplatin and irinotecan. Objective:to analyze patients` perception about difficulty of d
Publikováno v:
European Journal of Hospital Pharmacy. 23:A236.2-A236
Background Combining bevacizumab (BEV) 10 mg/kg with irinotecan (IRI) 125 mg/m 2 every 14 days represents a treatment option in recurrent gliobastoma multiforme (GBM) based on a phase II trial. When IRI is administered concurrently with enzyme induci
PS-051 Safety of abiraterone in metastatic castration resistant prostate cancer in clinical practice
Publikováno v:
European Journal of Hospital Pharmacy. 23:A236.1-A236
Background Abiraterone is approved for patients who have metastatic castration resistant prostate cancer (mCRPC). It irreversibly inhibits the products of the CYP17 gene, blocking the synthesis of androgens. Increased mineralocorticoids due to CYP17